Advice
The marketing authorisation for rosiglitazone (Avandia) has been withdrawn.
The SMC Advice has been removed from the website.
On 23 September2010 the European Medicines Agency’s (EMA) Committee on Medicinal Products for Human Use (CHMP) recommended the suspension of the marketing authorisation for Avandia Avandamet and Avaglim (rosiglitazone) as the benefits no longer outweigh the risks.
www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
Medicine details
- Medicine name:
- Rosiglitazone (Avandia®)
- SMC ID:
- 91/04
- Indication:
- Type 2 diabetes mellitus patients for whom metformin is inappropriate
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 08 March 2004